STOCK TITAN

[8-K] Eli Lilly & Co. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Eli Lilly and Company filed a Form 8-K dated 7 Aug 2025 under Item 2.02 to furnish, not file, a press release (Ex. 99.1) that announces the company’s financial results for the quarter ended 30 Jun 2025. The actual earnings figures are not included in this submission; investors must review the accompanying press release for details. No other material transactions or disclosures are presented. The filing re-affirms the company’s NYSE listings for its common stock and various note issues and indicates that Lilly is not an emerging-growth company. The document is purely administrative and carries no immediate financial metrics or guidance.

Eli Lilly and Company ha presentato un Modulo 8-K datato 7 agosto 2025 ai sensi del Punto 2.02 per fornire, senza depositare, un comunicato stampa (Ex. 99.1) che annuncia i risultati finanziari del trimestre terminato il 30 giugno 2025. Le cifre effettive degli utili non sono incluse in questa comunicazione; gli investitori devono consultare il comunicato stampa allegato per i dettagli. Non sono presentate altre operazioni materiali o divulgazioni. La presentazione riafferma le quotazioni della società alla NYSE per le azioni ordinarie e varie emissioni di obbligazioni, e indica che Lilly non è una società in crescita emergente. Il documento è puramente amministrativo e non contiene metriche finanziarie immediate o indicazioni.

Eli Lilly and Company presentó un Formulario 8-K fechado el 7 de agosto de 2025 bajo el Punto 2.02 para proporcionar, sin presentar, un comunicado de prensa (Ex. 99.1) que anuncia los resultados financieros del trimestre terminado el 30 de junio de 2025. Las cifras reales de ganancias no están incluidas en esta presentación; los inversores deben revisar el comunicado de prensa adjunto para obtener detalles. No se presentan otras transacciones materiales ni divulgaciones. La presentación reafirma las cotizaciones de la compañía en la NYSE para sus acciones comunes y varias emisiones de notas, e indica que Lilly no es una empresa de crecimiento emergente. El documento es puramente administrativo y no contiene métricas financieras inmediatas ni directrices.

Eli Lilly and Company2025년 8월 7일자 8-K 양식을 항목 2.02에 따라 제출하여, 회사의 2025년 6월 30일 종료 분기 재무 결과를 발표하는 보도자료(Ex. 99.1)를 제공했으나, 제출은 하지 않았습니다. 실제 수익 수치는 이 제출서에 포함되어 있지 않으며, 투자자들은 자세한 내용을 위해 첨부된 보도자료를 검토해야 합니다. 다른 중요한 거래나 공시는 없습니다. 이 제출은 회사의 NYSE 상장 주식과 여러 채권 발행물에 대한 상장을 재확인하며, Lilly가 신흥 성장 기업이 아님을 명시합니다. 이 문서는 순수 행정적 성격이며 즉각적인 재무 지표나 가이던스를 포함하지 않습니다.

Eli Lilly and Company a déposé un formulaire 8-K daté du 7 août 2025 sous l’item 2.02 afin de fournir, sans déposer officiellement, un communiqué de presse (Ex. 99.1) annonçant les résultats financiers du trimestre clos le 30 juin 2025. Les chiffres réels des bénéfices ne sont pas inclus dans cette soumission ; les investisseurs doivent consulter le communiqué de presse joint pour plus de détails. Aucune autre transaction ou divulgation importante n’est présentée. Le dépôt réaffirme les cotations de la société à la NYSE pour ses actions ordinaires et diverses émissions d’obligations, et indique que Lilly n’est pas une entreprise en croissance émergente. Le document est purement administratif et ne contient pas de mesures financières immédiates ni d’orientations.

Eli Lilly and Company hat am 7. August 2025 ein Formular 8-K unter Punkt 2.02 eingereicht, um eine Pressemitteilung (Ex. 99.1) bereitzustellen, jedoch nicht einzureichen, die die Finanzergebnisse für das Quartal zum 30. Juni 2025 ankündigt. Die tatsächlichen Gewinnzahlen sind in dieser Einreichung nicht enthalten; Investoren müssen die beigefügte Pressemitteilung für Details prüfen. Es werden keine weiteren wesentlichen Transaktionen oder Offenlegungen präsentiert. Die Einreichung bestätigt die NYSE-Notierungen des Unternehmens für seine Stammaktien und verschiedene Anleiheemissionen und weist darauf hin, dass Lilly kein wachstumsstarkes Unternehmen im Entstehen ist. Das Dokument ist rein administrativ und enthält keine unmittelbaren finanziellen Kennzahlen oder Prognosen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Administrative 8-K furnishes Q2 2025 earnings release; no numbers provided—impact neutral.

The filing merely signals that Lilly has released its second-quarter results via a separate press release. Because the actual revenue, EPS, or guidance data are absent, investors receive no new quantitative insight from this document alone. Its purpose is compliance—ensuring Regulation FD disclosure—and it neither alters valuation nor risk profile without the accompanying exhibit. As such, I view the market impact as neutral pending review of the press release itself.

Eli Lilly and Company ha presentato un Modulo 8-K datato 7 agosto 2025 ai sensi del Punto 2.02 per fornire, senza depositare, un comunicato stampa (Ex. 99.1) che annuncia i risultati finanziari del trimestre terminato il 30 giugno 2025. Le cifre effettive degli utili non sono incluse in questa comunicazione; gli investitori devono consultare il comunicato stampa allegato per i dettagli. Non sono presentate altre operazioni materiali o divulgazioni. La presentazione riafferma le quotazioni della società alla NYSE per le azioni ordinarie e varie emissioni di obbligazioni, e indica che Lilly non è una società in crescita emergente. Il documento è puramente amministrativo e non contiene metriche finanziarie immediate o indicazioni.

Eli Lilly and Company presentó un Formulario 8-K fechado el 7 de agosto de 2025 bajo el Punto 2.02 para proporcionar, sin presentar, un comunicado de prensa (Ex. 99.1) que anuncia los resultados financieros del trimestre terminado el 30 de junio de 2025. Las cifras reales de ganancias no están incluidas en esta presentación; los inversores deben revisar el comunicado de prensa adjunto para obtener detalles. No se presentan otras transacciones materiales ni divulgaciones. La presentación reafirma las cotizaciones de la compañía en la NYSE para sus acciones comunes y varias emisiones de notas, e indica que Lilly no es una empresa de crecimiento emergente. El documento es puramente administrativo y no contiene métricas financieras inmediatas ni directrices.

Eli Lilly and Company2025년 8월 7일자 8-K 양식을 항목 2.02에 따라 제출하여, 회사의 2025년 6월 30일 종료 분기 재무 결과를 발표하는 보도자료(Ex. 99.1)를 제공했으나, 제출은 하지 않았습니다. 실제 수익 수치는 이 제출서에 포함되어 있지 않으며, 투자자들은 자세한 내용을 위해 첨부된 보도자료를 검토해야 합니다. 다른 중요한 거래나 공시는 없습니다. 이 제출은 회사의 NYSE 상장 주식과 여러 채권 발행물에 대한 상장을 재확인하며, Lilly가 신흥 성장 기업이 아님을 명시합니다. 이 문서는 순수 행정적 성격이며 즉각적인 재무 지표나 가이던스를 포함하지 않습니다.

Eli Lilly and Company a déposé un formulaire 8-K daté du 7 août 2025 sous l’item 2.02 afin de fournir, sans déposer officiellement, un communiqué de presse (Ex. 99.1) annonçant les résultats financiers du trimestre clos le 30 juin 2025. Les chiffres réels des bénéfices ne sont pas inclus dans cette soumission ; les investisseurs doivent consulter le communiqué de presse joint pour plus de détails. Aucune autre transaction ou divulgation importante n’est présentée. Le dépôt réaffirme les cotations de la société à la NYSE pour ses actions ordinaires et diverses émissions d’obligations, et indique que Lilly n’est pas une entreprise en croissance émergente. Le document est purement administratif et ne contient pas de mesures financières immédiates ni d’orientations.

Eli Lilly and Company hat am 7. August 2025 ein Formular 8-K unter Punkt 2.02 eingereicht, um eine Pressemitteilung (Ex. 99.1) bereitzustellen, jedoch nicht einzureichen, die die Finanzergebnisse für das Quartal zum 30. Juni 2025 ankündigt. Die tatsächlichen Gewinnzahlen sind in dieser Einreichung nicht enthalten; Investoren müssen die beigefügte Pressemitteilung für Details prüfen. Es werden keine weiteren wesentlichen Transaktionen oder Offenlegungen präsentiert. Die Einreichung bestätigt die NYSE-Notierungen des Unternehmens für seine Stammaktien und verschiedene Anleiheemissionen und weist darauf hin, dass Lilly kein wachstumsstarkes Unternehmen im Entstehen ist. Das Dokument ist rein administrativ und enthält keine unmittelbaren finanziellen Kennzahlen oder Prognosen.

0000059478false00000594782025-08-072025-08-070000059478us-gaap:CommonClassAMember2025-08-072025-08-070000059478lly:A1.625NotesDueJune22026Member2025-08-072025-08-070000059478lly:A2.125NotesDueJune32030Member2025-08-072025-08-070000059478lly:A625Notesdue2031Member2025-08-072025-08-070000059478lly:A500NotesDue2033Member2025-08-072025-08-070000059478lly:A6.77NotesDueJanuary12036Member2025-08-072025-08-070000059478lly:A1625NotesDue2043Member2025-08-072025-08-070000059478lly:A1.700Notesdue2049Member2025-08-072025-08-070000059478lly:A1125NotesDue2051Member2025-08-072025-08-070000059478lly:A1375NotesDue2061Member2025-08-072025-08-07

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 7, 2025
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter) 
Indiana 001-06351 35-0470950
(State or Other Jurisdiction
of Incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
  


Lilly Corporate Center
Indianapolis,Indiana46285
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (no par value)LLYNew York Stock Exchange
1.625% Notes due 2026LLY26New York Stock Exchange
2.125% Notes due 2030LLY30New York Stock Exchange
0.625% Notes due 2031LLY31New York Stock Exchange
0.500% Notes due 2033LLY33New York Stock Exchange
6.77% Notes due 2036LLY36New York Stock Exchange
1.625% Notes due 2043LLY43New York Stock Exchange
1.700% Notes due 2049LLY49ANew York Stock Exchange
1.125% Notes due 2051LLY51New York Stock Exchange
1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 2.02. Results of Operations and Financial Condition.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 7, 2025, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2025.






Item 9.01. Financial Statements and Exhibits.

Exhibit No.Description
99.1
Press Release of Eli Lilly and Company, dated August 7, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).














































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski
Name:Donald A. Zakrowski
Title:Senior Vice President, Finance, and
Chief Accounting Officer
Date: August 7, 2025

FAQ

What did Eli Lilly (LLY) file on August 7 2025?

The company filed a Form 8-K to furnish its Q2 2025 earnings press release under Item 2.02.

Does the Form 8-K contain Eli Lilly's Q2 2025 financial numbers?

No. The actual financial metrics are in Exhibit 99.1, which is referenced but not reproduced in the filing text provided.

Which period’s results are covered by the press release?

The results pertain to the quarter ended June 30, 2025.

Is the press release deemed "filed" or "furnished"?

It is expressly furnished, meaning it is not subject to Section 18 liability unless incorporated elsewhere.

Did the filing disclose any other material events?

No additional material transactions, guidance updates, or leadership changes were disclosed.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

734.54B
944.35M
0.16%
83.87%
0.9%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS